Diapositiva 32 de 52
Notas:
One of the key results of the LIFE study was a significantly greater reduction in ECG-detected LVH with losartan-based therapy than with atenolol-based therapy despite similar reductions in BP.1
The importance of LVH reduction is illustrated by the fact that losartan-based treatment also prevented more cardiovascular morbidity and deaths than the one based on atenolol.
1. Dahlöf B, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003.
